Arcturus Therapeutics Files 8-K Amendment

TL;DR

Arcturus Therapeutics filed an amendment to its 8-K, tweaking prior financial disclosures.

AI Summary

Arcturus Therapeutics Holdings Inc. filed an amendment (8-K/A) on March 14, 2024, to its report originally dated March 7, 2024. This amendment pertains to the company's results of operations and financial condition, as well as financial statements and exhibits. The filing does not appear to introduce new financial figures but rather amends previous disclosures.

Why It Matters

This filing is an amendment to a previous report, indicating a correction or addition to previously disclosed information regarding Arcturus Therapeutics' financial condition and operations.

Risk Assessment

Risk Level: low — This is an amendment to a previous filing, likely for clarification or correction, rather than a report of new material events.

Key Players & Entities

• Arcturus Therapeutics Holdings Inc. (company) — Registrant
• March 7, 2024 (date) — Earliest event reported date
• March 14, 2024 (date) — Filing date
• Delaware (jurisdiction) — State of incorporation
• 10628 Science Center Drive, Suite 250 San Diego, California 92121 (address) — Principal executive offices
• (858) 900-2660 (phone_number) — Registrant's telephone number

FAQ

Key Financial Figures

• $0.001 — ch registered Common stock, par value $0.001 per share ARCT The Nasdaq Stock Mar
• $160.9 million — decrease in collaboration revenue from $160.9 million to $157.7 million for the fiscal year-e
• $157.7 million — boration revenue from $160.9 million to $157.7 million for the fiscal year-end and $28.2 milli
• $28.2 million — 7.7 million for the fiscal year-end and $28.2 million to $25.0 for the fiscal fourth quarter
• $25.0 — he fiscal year-end and $28.2 million to $25.0 for the fiscal fourth quarter 2023. Thi
• $3.2 million — or the fiscal fourth quarter 2023. This $3.2 million adjustment resulted in an updated net l
• $29.7 m — ment resulted in an updated net loss of $29.7 million, or $1.12 per share, and $11.7 mi
• $1.12 — n updated net loss of $29.7 million, or $1.12 per share, and $11.7 million, or $0.44
• $11.7 m — $29.7 million, or $1.12 per share, and $11.7 million, or $0.44 per share, for the fisc
• $0.44 — $1.12 per share, and $11.7 million, or $0.44 per share, for the fiscal year end and

Filing Documents

• e619365_8ka-arct.htm (8-K/A) — 28KB
• 0001193805-24-000364.txt ( ) — 201KB
• arct-20240307.xsd (EX-101.SCH) — 3KB
• arct-20240307_lab.xml (EX-101.LAB) — 33KB
• arct-20240307_pre.xml (EX-101.PRE) — 22KB
• e619365_8ka-arct_htm.xml (XML) — 4KB

02. Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition On March 7, 2024, the Company issued a press release announcing its financial results for fiscal year ended December 31, 2023 (the "Press Release"). Subsequent to the issuance of this Press Release, and during the completion of the Company's fiscal year-end audit, non-cash revenue adjustments were made resulting in a change to the final financial (Loss), the changes affected the fiscal fourth quarter only and resulted in a decrease in collaboration revenue from $160.9 million to $157.7 million for the fiscal year-end and $28.2 million to $25.0 for the fiscal fourth quarter 2023. This $3.2 million adjustment resulted in an updated net loss of $29.7 million, or $1.12 per share, and $11.7 million, or $0.44 per share, for the fiscal year end and fourth quarter end 2023, respectively. The Consolidated Balance Sheet as of fiscal year end December 31, 2023 was adjusted to reflect an increase in deferred revenue by $3.2 million offset by a decease to stockholders' equity. The Company's cash, cash equivalents, and restricted cash at December 31, 2023, and its statement in the Press Release regarding its cash runway expectations, are not affected by these adjustments. The Company's Annual Report on the Form 10-K for fiscal year ended December 31, 2023 has been filed with the SEC on March [14], 2023. In accordance with General Instructions B.2 of Form 8-K, the information included in Item 2.02 of this Current Report on Form 8-K/A shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or Securities Act of 1933, as amended, except as shall be

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description of Exhibit 104 Cover Page to this Current Report on Form 8-K in Inline XBRL

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Arcturus Therapeutics Holdings Inc. Date: March 14, 2024 By: /s/ Joseph E. Payne Name: Joseph E. Payne Title: Chief Executive Officer

View Full Filing

View this 8-K/A filing on SEC EDGAR